• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600664.SS
Share

Harbin Pharmaceutical Group Co., Ltd. Stocks

CN¥ 6.97Last Updated 09.10.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 2.78B

CN¥ 6.97
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Harbin Pharmaceutical Group Co., Ltd. functions as a leading pharmaceutical company, overseeing the complete process from drug discovery and development to manufacturing and global sales. The firm's activities span both domestic Chinese markets and international territories. Its business structure is segmented into seven key areas: Antibiotics, Small-Molecule Drug Formulations, Over-the-Counter (OTC) and Health Products, Modern Chinese Medicine, Biopharmaceutical products, Animal Vaccines, and Pharmaceutical Distribution services. The company's broad product portfolio features a comprehensive selection of penicillin and cephalosporin antibiotics, in addition to vital pharmaceutical intermediates. Its notable offerings include various types of injections, such as Shuang Huanglian and Danshen freeze-dried injections, alongside a wide array of oral medications like roxithromycin dispersible tablets, amoxicillin capsules, and specialized pediatric granules containing paracetamol. The product line also encompasses a diverse range of antibiotics, highlighted by multiple cephalosporin-based injections (e.g., ceftriaxone sodium, cefepime hydrochloride) and penicillin derivatives, alongside extracts from traditional Chinese medicine like Panax ginseng. Furthermore, the group manufactures essential medical protective gear, including disposable surgical and protective masks, as well as isolation and protective gowns. These products are distributed under numerous well-known brands, including Hongyan Yaopin, Guangwei, Renmin Tongtai, and Hayao, among others. The company's headquarters are located in Harbin, China.

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 600664.SS is 9.16 and suggests 24% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.10.2026 09:19

Twelve people were killed in an attack on the Riyadh airport

10.10.2026 16:01

What's Important in Small-Cap Stocks: Risks Associated with Webull, Levi's Outlook, and Vaxcyte's Success

10.10.2026 13:01

How soon will the AI bubble burst? Will France infect the Eurozone? What's wrong with Levi's jeans?

10.10.2026 06:47

Moderna hits four-year high as NYT reports U.S. cancer vaccine effort

10.10.2026 04:58

Palantir shares hit a new high: Barclays followed Goldman in recommending a buy

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026